2026 Interim report
Filed with HKEX · Stock code 2256 · · 97 pages · English
Corporate Information 2 Business Highlights 4 Financial Highlights 7 Management Discussion and Analysis 9 Other Information 37 Auditor’s Report on Review of Interim Condensed 71 Consolidated Financial Statements Interim Condensed Consolidated Statement of 72 Profit or Loss and Other Comprehensive Income Interim Condensed Consolidated Statement of Financial Position 73 Interim Condensed Consolidate
Earlier from Abbisko Cayman
- Voluntary announcement - abbisko therapeutics announces positive preliminary phase II results with lavengratinib (ABSK061) for the treatment of achondroplasia
- Poll results of the extraordinary general meeting held on September 17, 2026
- AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
- Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
- Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Later from Abbisko Cayman
- Next Day Disclosure Returns
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Abbisko Cayman into a list and get an email when it puts out news.
Follow Abbisko Cayman